Tags

Type your tag names separated by a space and hit enter

The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
J Thromb Haemost. 2006 Feb; 4(2):377-84.JT

Abstract

BACKGROUND

Precise assessment of clotting function is essential for monitoring of hemostatic treatment for hemophilias A and B.

MATERIALS AND METHODS

Clot waveform analysis and thrombin generation assays were performed on factor (F) VIII- and FIX-deficient plasmas, which had been reconstituted with known amounts of recombinant FVIII (rFVIII) and affinity-purified FIX respectively. Clot waveforms were assessed qualitatively and quantitatively by measuring the parameters clotting time, maximum coagulation velocity (Min1), and maximum coagulation acceleration (Min2). The thrombin generation assay was also assessed qualitatively and measurements made of time to peak and peak height.

RESULTS

Overall results obtained with both assays showed good correlation for both clotting factors confirming that the changes in clotting waveform reflected changes in thrombin generation. Both assays demonstrated a predictable dose response to the addition of FVIII or IX. However, clot waveform analysis was more sensitive than the thrombin generation assay, particularly in detecting very low levels (0-0.1 IU dL(-1)) of both factors.

CONCLUSIONS

These data suggest that the application of clot waveform analysis to the routine management of the hemophiliacs could increase our understanding of the clinical significance of low levels of FVIII and FIX that cannot be measured by assays in current use. This may be particularly useful in the management of hemophiliacs with inhibitors or undergoing gene therapy.

Authors+Show Affiliations

Department of Pediatrics, Nara Medical University, Nara, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

16420569

Citation

Matsumoto, T, et al. "The Measurement of Low Levels of Factor VIII or Factor IX in Hemophilia a and Hemophilia B Plasma By Clot Waveform Analysis and Thrombin Generation Assay." Journal of Thrombosis and Haemostasis : JTH, vol. 4, no. 2, 2006, pp. 377-84.
Matsumoto T, Shima M, Takeyama M, et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost. 2006;4(2):377-84.
Matsumoto, T., Shima, M., Takeyama, M., Yoshida, K., Tanaka, I., Sakurai, Y., Giles, A. R., & Yoshioka, A. (2006). The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. Journal of Thrombosis and Haemostasis : JTH, 4(2), 377-84.
Matsumoto T, et al. The Measurement of Low Levels of Factor VIII or Factor IX in Hemophilia a and Hemophilia B Plasma By Clot Waveform Analysis and Thrombin Generation Assay. J Thromb Haemost. 2006;4(2):377-84. PubMed PMID: 16420569.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. AU - Matsumoto,T, AU - Shima,M, AU - Takeyama,M, AU - Yoshida,K, AU - Tanaka,I, AU - Sakurai,Y, AU - Giles,A R, AU - Yoshioka,A, PY - 2006/1/20/pubmed PY - 2006/4/11/medline PY - 2006/1/20/entrez SP - 377 EP - 84 JF - Journal of thrombosis and haemostasis : JTH JO - J Thromb Haemost VL - 4 IS - 2 N2 - BACKGROUND: Precise assessment of clotting function is essential for monitoring of hemostatic treatment for hemophilias A and B. MATERIALS AND METHODS: Clot waveform analysis and thrombin generation assays were performed on factor (F) VIII- and FIX-deficient plasmas, which had been reconstituted with known amounts of recombinant FVIII (rFVIII) and affinity-purified FIX respectively. Clot waveforms were assessed qualitatively and quantitatively by measuring the parameters clotting time, maximum coagulation velocity (Min1), and maximum coagulation acceleration (Min2). The thrombin generation assay was also assessed qualitatively and measurements made of time to peak and peak height. RESULTS: Overall results obtained with both assays showed good correlation for both clotting factors confirming that the changes in clotting waveform reflected changes in thrombin generation. Both assays demonstrated a predictable dose response to the addition of FVIII or IX. However, clot waveform analysis was more sensitive than the thrombin generation assay, particularly in detecting very low levels (0-0.1 IU dL(-1)) of both factors. CONCLUSIONS: These data suggest that the application of clot waveform analysis to the routine management of the hemophiliacs could increase our understanding of the clinical significance of low levels of FVIII and FIX that cannot be measured by assays in current use. This may be particularly useful in the management of hemophiliacs with inhibitors or undergoing gene therapy. SN - 1538-7933 UR - https://www.unboundmedicine.com/medline/citation/16420569/The_measurement_of_low_levels_of_factor_VIII_or_factor_IX_in_hemophilia_A_and_hemophilia_B_plasma_by_clot_waveform_analysis_and_thrombin_generation_assay_ L2 - https://doi.org/10.1111/j.1538-7836.2006.01730.x DB - PRIME DP - Unbound Medicine ER -